成人多黏菌素类药代动力学系统综述
黏菌素甲磺酸钠常用负荷9 MIU后9 MIU/日分2-3次给药,多黏菌素B常用负荷100-200 mg后50-100 mg每12 h给药。危重症患者药代动力学复杂,受肾功能、体重、急性肾损伤、肾脏清除增强、血清白蛋白和肝功能等因素影响,需个体化调整剂量。
要点
- 黏菌素甲磺酸钠常用负荷9 MIU后9 MIU/日分2-3次给药。
- 多黏菌素B常用负荷100-200 mg后50-100 mg每12 h给药。
- 危重症患者药代动力学受肾功能、体重等因素影响,需个体化调整剂量。
核心结论
- 危重症患者中黏菌素和多黏菌素B药代动力学复杂,受肾功能、体重、急性肾损伤、肾脏清除增强、血清白蛋白和肝功能等因素影响。
- 这些因素需要个体化剂量调整以避免毒性并达到疗效。
- 模型引导的精准给药通过整合群体药代动力学参数、患者特异性变量和治疗药物监测,有望优化其使用,确保疗效、安全性和耐药预防之间的平衡。
主要发现
- 黏菌素甲磺酸钠常用方案为负荷9 MIU后9 MIU/日分2-3次给药,多黏菌素B常用方案为负荷100-200 mg后50-100 mg每12 h给药。
- 使用硫酸黏菌素的研究报告个体间变异较低,可能归因于硫酸黏菌素为活性药物制剂。
- 黏菌素表观分布容积在健康个体中通常低于危重症患者。
- 未接受透析的危重症患者中黏菌素甲磺酸钠清除率较高,约13 L/h;接受连续肾脏替代治疗者清除率范围为2.31至8.23 L/h。
- 接受连续肾脏替代治疗的患者中,黏菌素清除率高于黏菌素甲磺酸钠,分别为2.06-6.63 L/h和1.57-3.85 L/h。
关键数值与推荐
- 黏菌素在危重症患者中蛋白结合率为51%至79%。
- 多黏菌素B在危重症和急性病患者中表观分布容积相似,范围分别为6.3-33.1 L和6.22-38.6 L。
- 多黏菌素B在危重症和急性病患者中清除率几乎相似,范围为1.27-2.32 L/h。
- 危重症患者中多黏菌素B蛋白结合率为48.8%至92.4%。
- 肌酐清除率是与黏菌素甲磺酸钠和/或黏菌素及多黏菌素B清除率改变相关的最常见患者特征。
临床怎么用
- 临床应根据肾功能、体重、急性肾损伤、肾脏清除增强、血清白蛋白和肝功能等因素个体化调整黏菌素和多黏菌素B剂量。
- 可考虑采用模型引导的精准给药,整合群体药代动力学参数、患者特异性变量和治疗药物监测,以平衡疗效、安全性和耐药预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The pharmacokinetics of polymyxins are highly variable and conventional dosing regimens may likely lead to sub-optimal exposures and outcomes, particularly in critically ill patients with multi-drug-resistant infections. The aim of this systematic review is to describe the published pharmacokinetic data and to investigate variables that have been shown to affect the pharmacokinetics of colistimethate sodium, colistin, and polymyxin B in adult populations. METHODS: Sixty studies were identified. A total of 27 and 33 studies described the pharmacokinetics of colistin and polymyxin B, respectively. RESULTS: The most common dosing regimen for colistimethate sodium was a loading dose of 9 MIU, followed by 9 MIU/day in two to three divided doses, while for polymyxin B, a loading dose of 100-200 mg, followed by 50-100 mg every 12 h was given. Studies that used colistin sulfate instead of colistimethate sodium reported lower inter-individual variability, which may be attributed to the formulation of colistin sulfate being an active drug. The volume of distribution for colistin is typically lower in healthy individuals than in critically ill patients, owing to variations in physiological and pathological conditions. The clearance of colistimethate sodium in critically ill patients not undergoing dialysis was higher, around 13 L/h, compared with those receiving continuous renal replacement therapy, where clearance ranged from 2.31 to 8.23 L/h. In patients receiving continuous renal replacement therapy, clearance of colistin was higher compared with colistimethate sodium (2.06-6.63 L/h and 1.57-3.85 L/h, respectively). Colistin protein binding in critically ill patients ranged from 51% to 79%. The volume of distribution of polymyxin B was similar between critically ill and acutely ill patients, with range of 6.3-33.1 L and 6.22-38.6 L, respectively. Clearance of polymyxin B was also almost similar between critically ill and acutely ill patients (range of 1.27-2.32 L/h). There were two studies that reported free drug concentrations instead of the total drug concentrations of polymyxin B. In critically ill patients, protein binding ranged from 48.8% to 92.4% for polymyxin B. Creatinine clearance was the most common patient characteristic associated with altered clearance of colistimethate sodium and/or colistin, and polymyxin B. CONCLUSIONS: Critically ill patients exhibit complex pharmacokinetics for colistin and polymyxin B, influenced by renal function, body weight, and clinical factors such as acute kidney injury, augmented renal clearance, serum albumin, and liver function. These factors necessitate individualized dosing adjustments to avoid toxicity and achieve therapeutic efficacy. Model-informed precision dosing provides a promising approach to optimize their use by integrating population pharmacokinetic parameters, patient-specific variables, and therapeutic drug monitoring, ensuring a balance between efficacy, safety, and resistance prevention.
引用
- Zamri PJ, Lim SMS, Sime FB, et al. A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations. Clin Pharmacokinet. 2025. PMID: 40246790. doi:10.1007/s40262-025-01488-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。